Nonclinical precedent Request an invite

Kynamro: genotox, carcinogenicity and repro: done or skipped?

mipomersen · APOB (ASO)
Genotoxicity
Conducted; negative (Ames, mouse lymphoma, mouse micronucleus)
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Carcinogenicity
2-year SC mouse and rat: hepatocellular adenomas (mouse), skin/subcutis fibrosarcoma/histiocytoma, hemangiosarcoma
“The Committee concluded that hepatocellular adenomas and combined hepatocellular adenomas or carcinomas were drug-related in female mice administered 60 mg/kg/week mipomersen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse fertility/EFD and rabbit EFD (not teratogenic); rat PPND pup effects; juvenile rat study
“Mipomersen was not teratogenic in mice or rabbits at doses providing modest margins of exposure (2 to 5 times) compared to humans.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Safety pharmacology
hERG, mouse respiratory and Irwin studies; CV telemetry within 13-week monkey tox study
“Heart rate, mean arterial pressure and EKG were evaluated by telemetry in monkeys after single and repeat doses of 3 to 35 mg/kg/wk for 13 weeks (Study AS02).”
✓ VerifiedFDA pharmacology/toxicology review, p. 39Source ↗
Genotox: Ames
Negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Genotox: in vitro mammalian
Mouse lymphoma cytogenetics assay: negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Genotox: in vivo
Mouse micronucleus: negative
“Mipomersen sodium did not exhibit genotoxic potential in a battery of studies, including the in vitro Bacterial Reverse Mutation (Ames) assay, an in vitro cytogenetics assay using a mouse lymphoma cell line, and an in vivo micronucleus assay in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Carcinogenicity model
2-year mouse and rat (mipomersen plus species-specific surrogate)
“2-year carcinogenicity studies were conducted in both the mouse and the rat with mipomersen and the relevant species-specific surrogate.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Carcinogenicity timing
2-year rat and mouse studies completed before the marketing application and found adequate by ECAC
“Two year carcinogenicity studies of mipomersen were conducted in rats and mice. The Executive Carcinogenicity Assessment Committee found the studies adequate.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
hERG / QT
Negative in hERG assay
“Conclusion was mipomersen was negative in hERG assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 39Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Amvuttra

vutrisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Conducted: in vitro Ames, CHL chromosomal aberration and in vivo mouse bone marrow micronucleus; no genotoxicity

Defitelio

defibrotide · Fragmented DNA oligonucleotides
Negative: Ames assay and in vivo rat bone marrow micronucleus assay

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Givlaari

givosiran · ALAS1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Hibsago

bepirovirsen · HBV RNA (ASO)
Conducted; negative (Ames, mammalian cell chromosomal aberration, in vivo mouse micronucleus)

Izervay

avacincaptad pegol · C5 (aptamer)
Conducted: Ames, chromosomal aberration in mammalian cells, mouse micronucleus; all negative

Leqvio

inclisiran · PCSK9 (siRNA)
Conducted: standard panel, negative

Macugen

pegaptanib · VEGF-165 (aptamer)
Conducted (GLP); pegaptanib and 2'-FU/2'-FC nucleosides negative overall

Onpattro

patisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, mouse micronucleus; all negative

Oxlumo

lumasiran · HAO1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Qalsody

tofersen · SOD1 (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Conducted: bacterial reverse mutation, in vitro chromosomal aberration (human lymphocytes), rat bone-marrow micronucleus; all negative

Redemplo

plozasiran · APOC3 (siRNA)
Conducted: Ames, in vitro chromosomal aberration (TK6), in vivo mouse micronucleus; not genotoxic

Rivfloza

nedosiran · LDHA (siRNA)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Rytelo

imetelstat · Telomerase (oligo)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Spinraza

nusinersen · SMN2 (ASO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Tegsedi

inotersen · TTR (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Tryngolza

olezarsen · APOC3 (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Viltepso

viltolarsen · DMD exon 53 (PMO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
Conducted: mutagenic potential evaluated in in vitro and in vivo assays

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Wainua

eplontersen · TTR (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Waylivra

volanesorsen · APOC3 (ASO)
Conducted: bacterial reverse mutation, mouse lymphoma TK, mouse bone-marrow micronucleus; all negative

Zanvastro

zilganersen · GFAP (ASO)
Conducted: Ames, in vitro chromosomal aberration, mouse micronucleus; all negative

Summary across all 27 oligonucleotides →